Xencor to Participate at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company renowned for its innovative approach in developing engineered antibodies aimed at treating cancer and autoimmune diseases, has announced its participation in several upcoming investor conferences that will provide a platform for the company to present its strategic vision and innovations.

The conferences include the TD Cowen 46th Annual Health Care Conference on March 2, 2026, where Xencor's management will present at 3:50 p.m. ET, followed by the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, at 10:00 a.m. ET. Additionally, the Barclays 28th Annual Global Healthcare Conference will take place on March 11, 2026, with Xencor's presentation scheduled for 11:30 a.m. ET. Investors and interested parties can access live webcasts of these presentations via the “Events & Presentations” section of Xencor's website (www.xencor.com). For those unable to attend the live sessions, replays will be available on the company's site for a minimum of 30 days post-event.

With over 20 candidates in clinical development, Xencor utilizes its proprietary XmAb® technology to create engineered antibodies that improve therapeutic outcomes. The company’s focused research aims at transforming treatment options for patients suffering from complex diseases, demonstrating its commitment to innovation in the biopharmaceutical landscape. Xencor’s partnerships have also enabled the commercialization of several XmAb therapies, further solidifying its position in the market.

For more information about Xencor and its developments, interested individuals can visit their official website or contact Charles Liles, the company's representative.

Xencor, Inc. (NASDAQ:XNCR) is poised for a promising upcoming period as it prepares to participate in key investor conferences in March 2026. As a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer and autoimmune diseases, Xencor offers a compelling investment opportunity, particularly with over 20 candidates in clinical development and established collaborations for several marketed therapies.

Participating in the TD Cowen, Leerink Partners, and Barclays healthcare conferences, Xencor’s management will articulate its strategic roadmap and provide updates on clinical advancements and XmAb® technology's innovative applications. Investors should tune in to these presentations as they could significantly impact market sentiment and share price trajectories.

Given the increasing interest in innovative treatments for cancer and autoimmune diseases, Xencor is well-positioned to capitalize on this trend. The company’s proprietary XmAb technology, which enables enhanced therapeutic mechanisms, can offer unique competitive advantages over traditional therapies. Monitoring the announcements and discussions during these conferences will be crucial for gauging potential market reactions and understanding investor sentiment towards Xencor's future prospects.

Investors who are considering a position in Xencor might view the days leading up to these conferences as an opportune time for research and analysis. One strategy could be to buy shares ahead of the events to capitalize on potential positive market movement post-presentations, as strong updates could drive increased interest and investment in the stock.

In conclusion, Xencor’s upcoming participation at these conferences is a significant event for investors to watch closely. The company’s robust pipeline, combined with an innovative technological edge, positions it as an attractive prospect in the biopharmaceutical market. As always, potential investors should conduct thorough due diligence and consider market conditions before making any investment decisions.